Navigating skin complications post-Mpox vaccination in immunocompromised individuals
DOI:
https://doi.org/10.66344/jpad.34.3.2024.2822Keywords:
Monkeypox (MPX), Zoonotic Disease, Skin Complications, Immunocompromised, MPX VaccinationAbstract
The article discusses skin complications that may occur in immunocompromised individuals after receiving the MPX vaccine. These complications may include delayed hypersensitivity reactions, eczema dermatitis, vesiculobullous lesions, and other skin infections. A multifaceted approach is necessary to manage these complications, including thorough prevaccination assessments, reporting postvaccination problems, and collaborating with dermatologists and immunologists. Education and awareness initiatives targeting healthcare professionals and immunocompromised individuals are also crucial. By taking a proactive and patient-centered approach, healthcare providers can minimize risks and ensure equitable access to vaccination for all individuals.References
Subissi L, Stefanelli P, Rezza G. Human mpox: global trends, molecular epidemiology and options for vaccination. Pathog Glob Health. 2024;118(1):25–32.
Adnyana IMDM. Monkeypox and genital skin diseases: New challenges from a dermatological perspective. J Pak Assoc Dermatol. 2023;33(3):811–2.
Kumar AM, Chen ST, Merola JF, Mostaghimi A, Zhou XA, Fett N, et al. Monkeypox outbreak, vaccination, and treatment implications for the dermatologic patient: Review and interim guidance from the Medical Dermatology Society. J Am Acad Dermatol. 2023;88(3):623–31.
Ahmed SK, Mohamed MG, Dabou EA, Abuijlan I, Chandran D, El-Shall NA, et al. Monkeypox (mpox) in immunosuppressed patients. F1000Res. 2023;12:127.
Duong MT, Tebas P, Ancha B, Baron J, Chary P, Isaacs SN, et al. Combination of extended antivirals with antiretrovirals for severe Mpox in advanced human immunodeficiency virus infection: Case series of 4 patients. Open Forum Infect Dis. 2024;11(3):ofae110.
Grüner E, Grossegesse M, Stern D, Ober V, Eser TM, Reiling G, et al. Mpox-Specific Immune Responses Elicited by Vaccination or Infection in People With HIV. J Infect Dis. 2024;jiae138.
Lin YC, Wen TH, Shih WL, Vermund SH, Fang CT. Impact of vaccination and high-risk group awareness on the mpox epidemic in the United States, 2022–2023: a modelling study. EClinicalMedicine. 2024;68:102407.
Mazzotta V, Lepri AC, Matusali G, Cimini E, Piselli P, Aguglia C, et al. Immunogenicity and reactogenicity of modified vaccinia Ankara pre-exposure vaccination against mpox according to previous smallpox vaccine exposure and HIV infection: prospective cohort study. EClinicalMedicine. 2024;68:102420.
Gaspari AA. Clinical characteristics of monkeypox vaccine injection site reactions: A cohort of seven patients. JEADV Clin Pract. 2024;3(1):249–52.
Wolff Sagy Y, Zucker R, Hammerman A, Markovits H, Arieh NG, Abu Ahmad W, et al. Real-world effectiveness of a single dose of mpox vaccine in males. Nat Med. 2023;29(3):748–52.
Downloads
Published
How to Cite
Issue
Section
License
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
